Indications for NEXLETOL:
An adjunct to diet and maximally tolerated statin therapy, in patients with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Limitations of Use:
The effect of Nexletol on cardiovascular morbidity and mortality has not been determined.
180mg once daily.
Hyperuricemia. Assess serum uric acid as clinically indicated. History of gout. Increased risk for tendon rupture/injury (esp. >60yrs, renal failure); discontinue immediately if occurs; consider discontinuing if joint pain, swelling, or inflammation develop. History of tendon disorders/rupture: consider alternative therapy. Assess lipid levels within 8–12 weeks after initiation. Elderly. Severe hepatic (Child-Pugh C) or renal impairment (eGFR <30mL/min/1.73 m2). ESRD on dialysis. Pregnancy: discontinue if occurs. Nursing mothers: not recommended.
Adenosine triphosphate-citrate lyase (ACL) inhibitor.
Avoid concomitant simvastatin >20mg or pravastatin >40mg. Increased risk for tendon rupture with corticosteroid or fluoroquinoline drugs.
Upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, elevated liver enzymes; gout, BPH.